NFKB1 and rheumatoid arthritis: Notably, a cross-validated study revealed that Sarsasapogenin (Sar) could serve as a novel anti-RA drug by suppressing the expression of key regulators involved in DNA replication, cell cycle, and apoptosis, thereby impairing the NF-κB signaling pathway and ameliorating RA progression [238].